NAMD Submits Comments on Reopened 340B Ceiling Price Rule

On May 18, NAMD submitted comments to the Health Resources and Services Administration (HRSA) in response to reopened provisions of a proposed rule on the 340B drug discount program. NAMD called for HRSA to maintain its initially proposed “penny pricing” method for 340B drugs, for HRSA to align the 340B ceiling price for new drugs entering the market with the Medicaid drug rebate program, and for continued collaboration between CMS, HRSA, and the states to facilitate the sharing of 340B ceiling price information with Medicaid programs.

 Read full letter.

Comments are closed.